Tag:

Parkinson's disease

Latest Headlines

Latest Headlines

Phase II trial kicks off for sublingually delivered Parkinson's therapy

A sublingually delivered thin film strip to treat advanced Parkinson's disease kicked off its Phase II clinical trial following discussions with the FDA, Cynapsus Therapeutics announced July 16.

Chemical switch could be drug target for neurodegenerative disease

A chemical switch that controls the transformation of neural stem cells into neurons and keeps existing nerve cells in the brain alive may be a viable target for neurodegenerative disorders such as Alzheimer's, Parkinson's and autism.

Protein found in naked mole rats could shed light on Alzheimer's, Parkinson's development

A new study identifying a protein associated with the remarkable longevity of the naked mole rat may provide clues for preventing aging-related diseases in humans, like Alzheimer's and Parkinson's.

High protein levels linked to cell death in Parkinson's

Researchers may have discovered how a genetic mechanism in a common cause of Parkinson's works to destroy brain cells in patients--a finding that could help scientists develop new therapies for the devastating disease.

UCSF rolls out patient database to boost brain research

Researchers at the University of California, San Francisco, have launched a new online database to help reduce the time and cost of conducting clinical trials for brain ailments.

Impax gives it another go with a once-rejected Parkinson's drug

After a manufacturing problem irked the FDA and scared off partner GlaxoSmithKline, Impax Laboratories is resubmitting its investigational drug for Parkinson's disease, hoping it can clear an agency inspection and finally get its treatment on the market.

Stem cell therapy improves Parkinson's symptoms in monkeys

International Stem Cell Corp. is inching closer to bringing its stem cell therapy for Parkinson's to the FDA in hopes of eventually reversing the disease's symptoms in people.

Forest's CNS partner Adamas shoots for IPO gold in $69M offering

Now that it's steered its way successfully through the treacherous waters of a Phase II/III study for a new-and-improved drug for Parkinson's, Adamas Pharmaceuticals believes this is the right time to mount a $69 million IPO bid as it sets the stage for a pivotal trial.

Berg, Parkinson's Institute partner to find biomarkers

The Sunnyvale, CA-based Parkinson's Institute and Clinical Center and pharma company Berg are partnering to identify potential biomarkers to help diagnose and treat Parkinson's disease.

Compound protects mice from Parkinson's-like motor loss

In the Journal of Medicinal Chemistry, scientists report that they've found a new compound that may offer protection against Parkinson's disease.